Scientific Program

Scientific Program

The latest updates by world-renowned experts in the field of diabetes

We are planning an innovative and exciting program for ATTD 2021. The full program will be available shortly.

Review the confirmed topics and speakers below.

*Updated as of 16 November, 2020

First Name Last Name Country Topic
Michael Abràmoff USA Autonomous Artificial Intelligence and Diabetic Retinopathy: Safety, Efficacy and Equity
Jeffrey Alfonsi Canada Together with Mark Palmert – iSpy: Novel Carbohydrate Counting Smartphone App for Youth with Type 1 Diabetes
Stephanie Amiel UK From Hesiod to Hollywood: getting the best blood glucose for rational thinking
Katharine Barnard UK Together with Korey Hood: Patient Related Outcomes (PROs) – presentation of key instruments and how to use them (INSPIRE measures)
Richard Bergenstal USA Use of technology for the treatment of type 2 diabetes
Stephane Bidet France Artificial Intelligence applications to support decision management in insulin therapy
Bruce Bode USA Management of glucose in the hospital using computerized systems
Stefan Bornstein Germany Novel medications for diabetes to be used during COVID-19 pandemic
Charlotte Boughton UK Broadening usage of closed-loop
Nataša Bratina Slovenia Impact of patient reported outcomes on pediatric routine clinical work
Katarina Braune Germany Patient-centered innovation in healthcare
Bruce Buckingham USA A pivotal trial of Omnipod Horizon™ Automated Glucose Control System
Fergus Cameron Australia Debate: In the era of remote visits – do we still need A1c measures
Stuart Weinzimer – CON
Fergus Cameron – PRO
Anders Carlson USA Performance of studies on advanced hybrid closed-loop 780G
Antonio Ceriello Italy How to manage type 2 diabetes and obesity during the COVID-19 pandemic
Pratik Choudhary UK Transplantation – managing partial pancreas function or managing the failing pancreas
Mark Clements USA What do we need to develop/improve with the technology that we are using today
Kelly Close USA Harnessing the power of social media and peer support
Thomas Danne Germany
  • The SWEET project: benchmarking over 10 years is associated with improved HbA1c and increased use of diabetes technology in youth with type 1 diabetes worldwide
  • Ongoing clinical trials in INNODIA
Christophe De Block Belgium NAFLD/NASH in type 1 diabetes: overrated or underappreciated
Carine de Beaufort Luxembourg COVID-19 outbreak and Pediatric diabetes
Elisa De Franco UK Update on genes for Neonatal Diabetes
Hans DeVries The Netherlands New insulins: Foreseeable impact on diabetes therapy –
Once weekly insulins
Klemen Dovc Slovenia
  • Faster acting insulin analogues in closed-loop insulin delivery
  • Closed-loop and physical activity in youth with type 1 diabetes
Francis Doyle III USA Update on Artificial Pancreas engineering and clinical studies
David Dunger UK Innovative trial design in INNODIA
Steven Edelman USA Strategies for improvement of metabolic control in adults with T1D
Denice Feig Canada DEBATE: Should all pregnant women with diabetes take metformin during pregnancy
Yariv Yogev – CON
Denice Feig – PRO
Satish Garg USA Managing T1D-new-onsets and DKA through telehealth
Ahmad Haidar Canada multi-hormone closed-loop systems
Michael Haller USA Using tele-education with the ECHO model to reach primary care providers in rural areas to improve the level of care for people with diabetes
Tim Heise Germany New insulins: Foreseeable impact on diabetes therapy –
Smart Insulins
Pau Herrero UK Artificial Intelligence upgrades automated insulin delivery towards a fully closed-loop
Irl Hirsch USA
  • Lessons learned from the COVID-19 pandemic
  • How should reimbursement look after the COVID-19 pandemic
  • Insulin Affordability: will biosimilars help?
Korey Hood USA
  • Leveraging telehealth and digital tools to optimize use of diabetes devices
  • Together with Katharine Barnard: Patient Related Outcomes (PROs) – presentation of key instruments and how to use them (INSPIRE measures)
Roman Hovorka UK Use of the CamAPS FX closed-loop in the research and clinical investigation
Peter Jacobs USA Decision support and closed loop control during exercise:  new findings from clinical studies and larger data sets
Partha Kar UK Where two worlds collide: how social media and peer support can enhance clinical care
Boris Kovatchev USA Results of a study on Closed-Loop Control (CLC) system – Control IQ
Lori Laffel USA
  • Patient preferences for automatic insulin delivery
  • Telemedicine for routine follow up type 1 diabetes pediatric visits
Robert Lindsay UK Factors associated with stillbirth in women with diabetes
David Maahs USA NIH funded study: Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D: 4T Study
Chantal Mathieu Belgium Introduction INNODIA/INNODIA HARVEST study
Laurel Messer USA Artificial pancreas device upgrades—best practices for onboarding and follow-up
Othmar Moser Austria EASD/ISAP position statement on CGM/exercise in type 1 diabetes
Helen Murphy UK Pregnancy outcomes of 17,375 women with diabetes: National population-based cohort study
Omar Mustafa UK Glucose control during COVID-19 infection: targets and acute derangements
Steven Nissen USA Dual or triple GLP/GIPs as treatment for T2D
Simon O’Neill UK Diabetes UK – T2D perspective
Mark Palmert Canada Together with Jeff Alfonsi – iSpy: Novel Carbohydrate Counting Smartphone App for Youth with Type 1 Diabetes
Susana Patton USA Intervening on Hypoglycemia Fear in Parents of Young Children using Direct-to-Home Video-based Telehealth
William Polonsky USA Impact of PROs on adult clinical care: why, when and how?
Walter Pories USA Toxic Intestinal signals as a cause of type 2 diabetes and the metabolic syndrome
Eric Renard France Efficacy of Closed-loop Insulin Therapy in Adults Prone to Hypoglycemia – the International Diabetes Closed-Loop Trial Protocol 2
Michael Riddell Canada Monitoring the elite athlete with type 1
Francesco Rubino UK An international register for new onset diabetes during COVID-19 pandemic
Andrea Scaramuzza Italy Benefits and challenges of diabetes technology in children
Desmond Schatz USA Lessons from the nPOD
Anke Schulte Germany An integrated search for novel biomarkers
Eleanor Scott UK Week by week CGM profiles of pregnant women with type 1 diabetes
Jay Skyler USA
  • Diabetes Cardiovascular Outcome Trials – Current Status
  • Immunotherapy for type1 diabetes – Where are we now?
Amir Tirosh Israel Virtual Diabetes Clinic – the Dietitian Perspective
Maria Vasiloglou Switzerland Comparison of novel and traditional dietary assessment methods in diabetes patients
Stuart Weinzimer USA Debate: In the era of remote visits – do we still need A1c measures
Fergus Cameron – PRO
Stuart Weinzimer – CON
Emma Wilmot UK The effectiveness of isCGM: comparison of data from RCTs and routine-use
Yariv Yogev Israel DEBATE: Should all pregnant women with diabetes take metformin during pregnancy
CON – Yariv Yogev
PRO – Denice Feig
Eric Zijlstra Germany New insulins: Foreseeable impact on diabetes therapy –
Oral Insulin